The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
The Chemours CompanyNYSE: CC
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue dips below year-ago levels
Q2 FY2026 cost of revenue of $1.31B fell 2.4% year over year, behind the +2.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Cost of revenue amounted to 84.5% of revenue in FY2025, up 4.4 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +2.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 4.91B USD
- Year-over-year change
- +5.9%
- 4-year CAGR
- -0.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.91B | +5.9% |
| FY2024 | 2024-12-31 | 4.63B | -3.0% |
| FY2023 | 2023-12-31 | 4.77B | -8.5% |
| FY2022 | 2022-12-31 | 5.22B | +5.1% |
| FY2021 | 2021-12-31 | 4.96B | — |
Cost of Revenue vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 cost of revenue of $4.91B is the 7th highest of the 19 companies compared; the peer median is $2.3B.
- Its year-over-year change of +2.1% is the 11th highest of 19, against a peer median of +4.5%.
- Cost of revenue amounts to 84.7% of revenue for CC, versus a peer median of 67.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $27.27B | -7.7% | -14.5% | 85.3% | |
| LTM Jun 2026 | $22.14B | +6.1% | -3.7% | 62.4% | |
| LTM Sep 2026 | $10.76B | +3.2% | -2.4% | 94.1% | |
| LTM Jun 2026 | $9.84B | +13.8% | -0.4% | 59.9% | |
| LTM Sep 2026 | $8.89B | +7.7% | +0.2% | 68.4% | |
| LTM Jun 2026 | $6.23B | -13.5% | -5.7% | 62.5% | |
| LTM Jun 2026 | $4.91B | +2.1% | -2.0% | 84.7% | |
| LTM Jun 2026 | $3.47B | +0.8% | -0.2% | 67.4% | |
| LTM Jun 2026 | $2.8B | -1.9% | -6.9% | 77.1% | |
| LTM Aug 2026 | $2.39B | -1.6% | -5.2% | 67.2% | |
| LTM Sep 2026 | $2.21B | +52.7% | -2.5% | 63.4% | |
| LTM Mar 2026 | $1.45B | +0.0% | -2.9% | 80.9% | |
| LTM Sep 2026 | $1.32B | +8.8% | -3.1% | 65.0% | |
| LTM Jun 2026 | $1.3B | -5.9% | -6.5% | 70.6% | |
| LTM Sep 2026 | $1.25B | +7.5% | -0.4% | 82.4% | |
| LTM Jun 2026 | $1.11B | +5.9% | +4.2% | 65.4% | |
| LTM Mar 2026 | $639.27M | +25.9% | -1.7% | 78.0% | |
| LTM Jun 2026 | $389.54M | +51.8% | +6.2% | 51.5% | |
| LTM Mar 2026 | $139.77M | -31.1% | -28.1% | 126.9% | |
| Peer median (excluding CC) | $2.3B | +4.5% | -2.7% | 67.9% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.